Apple (AAPL) to hold new iPhone launch event on September 9th
Newsquawk Staff ·
Apple (AAPL) to hold new iPhone launch event on September 9th.
What it means
Apple's annual flagship launch sits in the early autumn slot the company has occupied for years, and the pattern around it is well established: the stock tends to firm into the event on expectation and soften on the reveal itself, the classic buy-the-rumour, sell-the-news cadence, with the post-event direction then set by preorder signals and carrier and channel checks rather than by anything said on stage. What separates one year from another is not the hardware spec sheet but the perceived pricing and the length of the replacement cycle it implies, since those feed directly into services attach and the average selling price assumptions the Street carries. Suppliers in the handset chain tend to trade the event as a read-through on build orders, so the peer set reaction often carries as much information as the parent. The follow-ons that have historically mattered are preorder lead times in the days after, any commentary on China demand, and whether management signals a supercycle or a maintenance refresh. The event date itself is procedural; the information content arrives around it.
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation
- Daily US Equity Opening News - SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at USD 1.25tln valuation; AAPL foldable iPhone launches; SKHY cancels Solidigm Nasdaq IPO plans; WDC beat and raise
Related headlines
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans8 hours ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS10 hours ago
- OpenAI reveals plans for an in-house exabyte-scale storage system10 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter10 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)11 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed11 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders13 hours ago
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease7 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL8 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 202710 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability11 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer13 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM14 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years14 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months15 hours ago